HWHelen H. Wang

Helen H. Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helen H. Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Nour Sneige

    Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

    2 shared publications
  • Amanda Elliott

    Division of Endocrinology, Department of Medicine; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication
  • Andra R. Frost

    Department of Pathology, The George Washington University Medical Center, Washington, DC

    1 shared publication
  • Anna Zelfond Feldman

    Beth Israel Deaconess Medical Center

    1 shared publication
  • Barbara Ducatman

    Department of Pathology, Robert C. Byrd Health Sciences Center of West Virginia University, Morgantown, West Virginia

    1 shared publication
  • Bradley Gornstein

    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA

    1 shared publication

Latest Publications

  • Colorectal dysplasia in chronic inflammatory bowel disease: a contemporary consensus classification and interobserver study

    by Noam Harpaz, John R. Goldblum, Neil A. Shepherd, Robert H. Riddell, Carlos A. Rubio, Michael Vieth, Helen H. Wang, Robert D. Odze


  • Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing

    by Michiya Nishino, Roselyn Mateo, Holly Kilim, Anna Feldman, Amanda Elliott, Changyu Shen, Per-Olof Hasselgren, Helen Wang, Pamela Hartzband, James V. Hennessey

    Background: Molecular testing (MT) refines risk stratification for thyroid nodules that are indeterminate for cancer by fine needle aspiration (FNA) cytology. Criteria for selecting nodules for MT vary and remain largely untested, raising questions about the best strategy for maximizing the usefulness of MT while minimizing the harms of overtesting. We used a unique data set to examine the effects of repeat FNA cytology-based criteria for MT on management decisions and nodule outcomes. Methods: This was a study of adults (age 25–90 years; 281 women and 72 men) with cytologically indeterminate (Bethesda III/IV) thyroid nodules who underwent repeat FNA biopsy and Afirma Gene Expression Classifier (GEC) testing ( N = 363 nodules from 353 patients) between June 2013 and October 2017 at a single institution, with follow-up data collected until December 2019. Subgroup analysis was performed based on classification of repeat FNA cytology. Outcomes of GEC testing, clinical/sonographic surveillance of unresected nodules, and histopathologic diagnoses of thyroidectomies were compared between three testing approaches: (i) Reflex (MT sent on the basis of the initial Bethesda III/IV FNA), (ii) SemiRestrictive (MT sent if repeat FNA is Bethesda I–IV), and (iii) Restrictive (MT sent only if repeat FNA is Bethesda III/IV) testing approaches. Results: Restricting MT to nodules that remain Bethesda III/IV on repeat FNA would have missed 4 low-risk cancers and 3 noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) (collectively 2% of the test population) but would have avoided diagnostic surgery for 42 benign nodules (12% of the test population). The Restrictive testing strategy was more specific (delta 0.126 confidence interval [CI 0.093 to 0.159] and 0.129 [CI 0.097 to 0.161], respectively) but less sensitive (delta −0.339 [CI −0.424 to −0.253] and −0.340 [CI −0.425 to −0.255], respectively) than the Reflex and SemiRestrictive approaches for detecting NIFTP or cancer. Conclusions: Repeat FNA cytology can guide the selection of cytologically indeterminate thyroid nodules that warrant MT. The Restrictive model of performing Afirma GEC only on nodules with two separate biopsies showing Bethesda III/IV cytology would reduce the rate of diagnostic surgery for histologically benign nodules while missing only rare low-risk tumors. Given the low but nontrivial risks of thyroidectomy, the higher specificity of the Restrictive testing approach disproportionately outweighs the potential harms.


  • Reporting thyroid FNA before and after implementation of the Bethesda system—one institution's experience

    by Kathriel J. Brister, Remmi S. Singh, Helen H. Wang

    Background The Bethesda System for Reporting Thyroid Cytopathology was published in 2008 and was implemented at Beth Israel Deaconess Medical Center (BIDMC) in June, 2010. Prior to this date, our diagnostic scheme was similar to the Bethesda System, except for the category of “Atypia/Follicular Lesion of Undetermined Significance” (AUS). This study evaluates the impact of the Bethesda System on the rate and the positive predictive value (PPV) of the diagnostic categories at BIDMC. Methods We performed a retrospective review of all thyroid fine‐needle aspirations (FNAs) during the time periods January, 2006 to November, 2008 and June, 2010 to July, 2011 and the subsequent thyroidectomy specimens. Results Post‐Bethesda System, diagnoses that are equivocal for diverse reasons and which have wide‐ranging PPVs are now all grouped into the AUS category, and the proportion of cases that are in the atypical/AUS category rose from 3.7% in the pre‐Bethesda period to 12% in the post‐Bethesda period. Conclusion The AUS category has a PPV approaching 50% in our lab. This creates uncertainty regarding the appropriate management for this category and may cause unnecessary overuse of molecular testing for cases in the AUS category. Diagn. Cytopathol. 2014.


  • Fine needle aspiration cytology of lobular carcinoma in situ on ThinPrep®

    by Gamze Ayata, Helen H. Wang

    Lobular carcinoma in situ (LCIS) of the breast is a recognized marker for increased risk of invasive carcinoma and has well-established histologic criteria. However, its detection and diagnosis on FNA of breast has not been well defined. Cytology slides (all ThinPrep®) of 11 cases with biopsy-proven LCIS at Beth Israel Deaconess Medical Center were reviewed. All 11 cases showed tight and/or loosely cohesive clusters of crowded mildly enlarged nuclei and ten of 11 showed at least moderate cellularity. Single epithelial cells, small but prominent nucleoli, intracytoplasmic lumina, and two distinct epithelial-cell populations were also noted in some cases. As none of these features is specific for LCIS, it would be prudent to report such lesions as atypical so that a core biopsy or excisional biopsy will be performed before definitive treatment. The original FNA diagnosis of the 11 cases ranged from epithelial proliferation without atypia to carcinoma. Three of the 11 cases had fibroadenomas on histology with extensive involvement by LCIS. Since management for LCIS is different from that for invasive carcinoma or DCIS, it should be considered and distinguished from the latter two in cases suspicious for carcinoma on FNA. Diagn. Cytopathol. 2005;32:276–280.


  • Reporting thyroid fine-needle aspiration: Literature review and a proposal

    by Helen H. Wang

    Reporting schemes for thyroid fine‐needle aspirations in the literature were reviewed and classified according to the number of categories in the scheme and the significance of each category. The sensitivity, specificity, and positive predictive and negative values were determined for each scheme, if possible. A reporting scheme based on the probability of finding carcinoma on histology is proposed. Diagn. Cytopathol. 2006;34:67–76.


  • Interobserver agreement of a probabilistic approach to reporting breast fine‐needle aspirations on ThinPrep®

    by Bradley Gornstein, Timothy Jacobs, Yvan Bédard, Charles Biscotti, Barbara Ducatman, Lester Layfield, Grace McKee, Nour Sneige, Helen Wang

    We have previously demonstrated the accuracy and reproducibility of a probabilistic/categorical approach for reporting breast fine‐needle aspiration (FNA). However, the interobserver agreement in the application of this approach has not been assessed. Twenty breast FNA cases (each on one ThinPrep® slide) were pulled from the cytology files of Beth Israel Deaconess Medical Center. The cases included benign epithelial proliferative lesions (6), DCIS (4), and infiltrating carcinoma (10), as shown by subsequent histology. Six pathologists with 14–25 yr of experience in interpreting breast FNA and 0–8 yr of experience with ThinPrep preparations rendered diagnoses according to the probabilistic approach. The kappa statistic for the unremarkable/proliferative, atypical, suspicious, and positive categories were 0.64, 0.08, 0.43, and 0.75, respectively (P < 0.001 for all except for the atypical category [P = 0.09]). Spearman's rho correlating the individual pathologist's diagnosis and the histologic diagnosis ranged from 0.51 (P = 0.02) to 0.78 (P < 0.0001). This was not correlated with the pathologists' years of experience interpreting breast FNA (P = 1.0) or with their years using ThinPrep preparations for breast FNA (P = 0.96). In conclusion, the interobserver agreement was excellent for the positive category in the probabilistic approach, poor for the atypical category, and fair to good for the other categories. The specific level of experience interpreting breast FNA or using ThinPrep among experienced pathologists did not seem to influence their accuracy in reporting the cases in our study. Diagn. Cytopathol. 2004;30:389–395.


  • Interobserver variability in the classification of proliferative breast lesions by fine‐needle aspiration: Results of the Papanicolaou Society of Cytopathology study

    by Mary K. Sidawy, Mark H. Stoler, William J. Frable, Andra R. Frost, Shahla Masood, Theodore R. Miller, Steven G. Silverberg, Nour Sneige, Helen H. Wang